SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the quarter ended June 30, 2015 after market close on Monday, August 10, 2015. Biocept management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
Individuals interested in participating on the conference call may do so by dialing (877) 407-4018 for domestic callers and (201) 689-8471 for international callers. Those interested in listening to a webcast of the live conference call may do so by visiting http://ir.biocept.com/events.cfm.
A replay of the conference calls will be available for 48 hours following the conclusion of the call by dialing (877) 870-5176 for domestic callers or (858) 384-5571 for international callers, and entering reservation code 13615125. A webcast replay will be available for 90 days at http://ir.biocept.com/events.cfm.
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for melanoma, OncoCEE-GA™ for gastric cancer, OncoCEE-BR™ for breast cancer and OncoCEE-LU™ for non-small cell lung cancer, and plans to introduce CLIA-validated tests for colorectal, prostate and other solid tumors in the near term.